Anti-CEACAM5 therapeutic antibody (Pre-made Labetuzumab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Labetuzumab (marketed under the trade name CEA-CIDE) is a humanized IgG1 monoclonal antibody for the treatment of colorectal cancer. It selectively binds to carcinoembryonic cell adhesion molecule 5.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-288-1mg	1mg	Inquiry
GMP-Bios-ab-288-10mg	10mg	Inquiry
GMP-Bios-ab-288-100mg	100mg	Inquiry
GMP-Bios-ab-288-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Anti-CEACAM5 therapeutic antibody (Pre-made Labetuzumab biosimilar,Whole mAb ADC)
INN Name	Labetuzumab
Target	CEACAM5
Format	Whole mAb ADC
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2015
Year Recommended	2016
Companies	Immunomedics
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Colorectal cancer;Ovarian cancer;Breast cancer
Development Tech	na